Allorion Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 by Qiang Ding and Fang Li, developing novel small-molecule therapies for cancer and autoimmune disease. Operating from Natick, Massachusetts and Guangzhou, China, Allorion applies mutant-selective and isoform-specific medicinal chemistry across a pipeline that includes ARTS-011 (a TYK2 inhibitor), ARTS-021 (a CDK2 inhibitor targeting CCNE1-amplified tumors), and ARTS-023/AVZO-023 partnered with Avenzo Therapeutics, alongside an exclusive option and global license agreement with AstraZeneca for an allosteric EGFR L858R inhibitor. The company is a drug-discovery organization backed by Qiming Venture Partners and INCE Capital; it markets internal data and high-throughput screening platforms but publishes no public developer program, API, SDK, or machine-readable specification.
Allorion Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Oncology.
Allorion Therapeutics’ developer surface includes product news and 13 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.